In order to ensure 2023 billing, testing must be activated before the end of the year, or within 30 days of proband sample collection (if sample was collected in 2023). For Exome, Genome, or Xpanded testing, if you do not expect parental samples to be received in time for testing to be activated with 2023 billing, please contact us at to determine how to proceed.

GeneDx logo


GeneDx contributes to a wide range of studies and research initiatives. Our team collaborates with top researchers, clinicians and institutions to further progress the field of genetics and genomics.

October 26, 2022 | BMC (Springer Nature)

Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation

Acute myeloid leukemia (AML) is the most common type of leukemia with a 5-year survival of 24%. Sema4 researchers, in partnership with Chungnam National University College of Medicine, South Korea and the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, have discovered that an estrogen-related receptor (ERRα) plays an role in AML development. These findings present ERRα as a new therapeutic target for drug development with potential to improve treatment response for blood cancers.

Read more
October 8, 2022 | American Academy of Pediatrics

Genomic Evaluation for Mitochondrial Disease in 1,935 Infants

This study focuses on mitochondrial disease phenotypes and genotypes in infants who have undergone rapid DNA sequencing. As more NICUs are utilizing this technology, it remains an open question if one should also include rapid mitochondrial DNA (mt-DNA) testing. This study evaluates the incidence of mitochondrial disease caused by both n-DNA and mt-DNA in NICU patients.

Read more
September 9, 2022 | Genetics in Medicine

Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants

This large study of 404 individuals with CTNNB1 variants provides a more comprehensive understanding of CTNNB1-related phenotypes and related health needs, and confirms that cerebral palsy (CP) is a common feature amongst individuals with CTNNB1 variants.

Read more
February 2, 2021 | JAMA

Molecular Diagnostic Yield of Exome Sequencing in Patients With Cerebral Palsy

Among patients with cerebral palsy who underwent exome sequencing, the prevalence of pathogenic and likely pathogenic variants was 32.7% in a cohort that predominantly consisted of pediatric patients and 10.5% in a cohort that predominantly consisted of adult patients.

Read more
January 28, 2021 | American Journal of Human Genetics

Mutation-specific pathophysiological mechanisms define different neurodevelopmental disorders associated with SATB1 dysfunction

Multiple lines of independent evidence to show that different variant types in a single gene, SATB1, cause clinically overlapping but distinct neurodevelopmental disorders.

Read more
January 25, 2021 | Genetics in Medicine

CDK19-related disorder results from both loss-of-function and gain-of-function de novo missense variants

CDK19 de novo missense variants are responsible for a novel neurodevelopmental disorder.

Read more
| Genetics In Medicine

Uniparental disomy in a population of 32,067 clinical exome trios

Trio exome sequencing (ES) presents a comprehensive method for detection of UPD alongside sequence and copy-number variant analysis.

Read more
January 20, 2021 | Genetics in Medicine

Variants in GNAI1 cause a syndrome associated with variable features including developmental delay, seizures, and hypotonia

GNAI1-related NDD is most often characterized by severe to profound delays, hypotonia, epilepsy that ranges from self-limiting to intractable, behavior problems, and variable mild dysmorphic features.

Read more
January 7, 2021 | American Journal of Human Genetics

A dyadic approach to the delineation of diagnostic entities in clinical genomics

The delineation of disease entities is complex, yet recent advances in the molecular characterization of diseases provide opportunities to designate diseases in a biologically valid manner. Here, we have formalized an approach to the delineation of Mendelian genetic disorders.

Read more
| American Journal of Human Genetics

De novo variants in POLR3B cause ataxia, spasticity, and demyelinating neuropathy

We expand the spectrum of disorders associated with pathogenic variants in POLR3B to include a de novo heterozygous POLR3B-related disorder.

Read more
January 6, 2021 | Epilepsia

Expanding the phenotype of PIGS-associated early onset epileptic developmental encephalopathy.

Further delineation of the molecular spectrum of PIGS-related disorders would improve management, help develop treatments, and encourage the expansion of diagnostic genetic testing to include this gene as a potential cause of neurodevelopmental disorders and epilepsy.

Read more
August 9, 2019 | Advances in Molecular Pathology

The Evolution of Constitutional Sequence Variant Interpretation

This GeneDx co-authored review provides education to the clinical pathology field on the practice of sequence variant interpretation. In addition to describing the evidence types currently utilized in variant interpretation, the authors also review the history of this practice and highlight future directions the field may take.

Read more